Compare CNXC & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNXC | ANIP |
|---|---|---|
| Founded | 1991 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 2020 | 1999 |
| Metric | CNXC | ANIP |
|---|---|---|
| Price | $33.91 | $74.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $69.00 | ★ $107.33 |
| AVG Volume (30 Days) | ★ 1.3M | 318.7K |
| Earning Date | 04-15-2026 | 05-11-2026 |
| Dividend Yield | ★ 4.10% | N/A |
| EPS Growth | N/A | ★ 419.23 |
| EPS | N/A | ★ 3.32 |
| Revenue | ★ $9,825,771,000.00 | $206,547,000.00 |
| Revenue This Year | $5.17 | $19.88 |
| Revenue Next Year | $2.51 | $15.77 |
| P/E Ratio | ★ N/A | $22.35 |
| Revenue Growth | 2.15 | ★ 2.47 |
| 52 Week Low | $29.35 | $56.71 |
| 52 Week High | $66.00 | $99.50 |
| Indicator | CNXC | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 48.83 | 41.34 |
| Support Level | $31.63 | $74.28 |
| Resistance Level | $44.40 | $85.12 |
| Average True Range (ATR) | 1.85 | 2.61 |
| MACD | 0.60 | -0.05 |
| Stochastic Oscillator | 81.68 | 31.01 |
Concentrix Corp is a technology and services company. It designs, implements, and manages end-to-end solutions, including customer experience process optimization, technology development and design engineering, front- and back-office automation, analytics, and business transformation services. The company serves clients across multiple industry verticals, helping them manage customer engagement and operational processes throughout the customer lifecycle. The company operates in a single operating segment. It generates revenue through the provision of technology and services under contractual arrangements. Geographically, the company generates the maximum revenue from the Philippines and the rest from India, the United States, Great Britain, Germany, Canada and Other countries.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.